You should consider shares of CRISPR Therapeutics AG (NASDAQ:CRSP) and Hi-Crush Inc. (NYSE:HCR) if you are looking for a great stocks to invest in. Starting with the CRSP shares, which traded at $66.03 at the close of the recent session, gaining 0.58%. On Thursday, the company’s shares shed $0.38 from its value which represented in intraday trading. The stock is now 81.50% higher in year-to-date (YTD) trading. CRSP’s intraday high was $66.3521 while its lowest price touched $64.06. The stock’s 52-week high price is $74.00, which means the current price is at -10.77%. In terms of trading activity, the daily trading volume rose to 1111171 against 200-day average trading volume of 687,144 shares.
What are analyst forecasts for CRISPR Therapeutics AG (NASDAQ:CRSP)?
At a consensus rating of 4.27, CRSP is trending as a streaking Moderate Buy, as it has been the case a month ago when 12 analysts called it a Moderate Buy. Two months ago, 12 analysts recommended, on average, that CRSP stock is a Moderate Buy. The Healthcare company’s shares’ overall bullish trend saw it close higher on Thursday compared to its opening price of $65.32 on the day.
Forecasts for CRISPR Therapeutics AG (NASDAQ:CRSP) give the stock a fair value for the growth of 17.46% from its last price. The 12-month price forecast for the stock by analysts puts the stock’s mean price target at $80.00, which means the price per share could rise by nearly $13.97. The price range target is between a low of $28.00 and a high of $104.00. The stock would need to gain by about $36.51 to hit the estimated high or 0.34% from its 12-month low.
The consensus among 16 analysts is that it is a good time for one to Overweight in the CRISPR Therapeutics AG. 12 analysts rate CRSP as a Buy, with 2 of 16 analysts rate it as a Sell. 0 have valued the stock as Overweight and 2 have recommended that investors Hold.
CRISPR Therapeutics AG (NASDAQ:CRSP) Upgrades and Downgrades
In terms of rating changes, William Blair on November 19, 2019, Upgrade CRISPR Therapeutics AG (CRSP) at Outperform. Analysts at Oppenheimer have assigned a Outperform rating for the stock in their research note on November 12, 2019 with an estimated price target of $65. Moreover, Jefferies analysts issued a rating of Buy for the stock on August 01, 2019, giving it a price target of $64 for the next 12 months. On July 26, 2019, the stock earned a Buy rating due to an analyst call from Canaccord Genuity, while analysts from ROTH Capital on June 10, 2019 suggested that the stock is Buy.
Hi-Crush Inc. (NYSE:HCR) adds -$0.03 on Thursday
The HCR stock has tanked -80.59% year-to-date and is currently trading at $0.69, which is -86.64% below its 52-week high. The company shares lost -3.49% on the day and have risen nearly 3.69% off a low hit. At current levels, Hi-Crush Inc. has a valuation of about $673.10M. As of 12/12/19, this stock has risen 1.21% during the week and closed at $0.72 in the previous session. However, recent Hi-Crush Inc. stock performance shows that HCR shares are -33.84% down over the last month, and -66.60% down for the last three months.
Earnings per share (EPS) estimates for the current quarter are -$0.07, with the trailing 12-month share earnings at -$4.04. The ratio is expected to be down by -118.30% for the current year 2019 and -34.60% for next year. Over the next 5-year period, earnings per share will be -1.42%. But will the HCR stock surprise in the current quarter results, where the -$0.03 actual EPS reported on 9/29/2019 surprised by 57.10% or was higher by $0.04 from the estimated -$0.07.
Sales Growth to decline -4.70% for the year
How well will Hi-Crush Inc. perform as a business over the current quarter, year and next 5-year period? Compared to the year-ago quarter, analysts forecast the company to bring in between $133.48M and $165.3M in current quarter sales. The consensus estimated for the current quarter is $148.48M from sales. Forecasts for this fiscal year are between $642M and $674M and the consensus estimate for sales is at $657.89M. HCR has its next quarter sales estimates at between $119.45M and $150M, with the quarter-over-quarter growth estimates at -20.70% and the annual growth forecast for the year at -4.70%.
Who owns shares in Hi-Crush Inc. (HCR)?
Vanguard Group, Inc. (The) tops the list of institutional owners as it is holding 3.46 million shares or 3.43% of shares outstanding. Renaissance Technologies, LLC and Citigroup Inc. held 1.48 million and 921349.0 representing 1.47% and 0.91% respectively at the close of the last trading session. As of Sep 29, 2019, Geode Capital Management, LLC accounted for 703915.0 shares at over 1.22 million. This represented 0.70% of shares outstanding. JP Morgan Chase & Company held 563198.0 shares at over 979964.0 representing 0.56% of shares outstanding.
HCR Insider Activity
On 6/07/2019, by the name Rasmus Robert E bought 100000.0 shares worth $163000.0 at the price of $1.63 per share. Filings also show that Oehlert Michael Alan bought a total of 56000.0 shares on 6/07/2019 valued at $99100.0. Since the last insider activity, the company’s share price has dropped -60.45%.